Elizabeth Evans
About Elizabeth Evans
Elizabeth Evans serves as the Chief Operating Officer at Vaccinex, where she has significantly contributed to the company's growth and clinical development efforts in immuno-oncology and neurodegenerative diseases. She holds a Ph.D. in Pathology and has extensive academic and research experience in biology, microbiology, and immunology.
Work at Vaccinex
Elizabeth Evans serves as the Chief Operating Officer at Vaccinex, a role she has held since 2021. Prior to this position, she was the Senior Vice President of Discovery and Translational Medicine, a position she has occupied since 2020. In her roles, she has been instrumental in establishing productive relationships with collaborators, partners, and investors. Evans has contributed significantly to the company's growth, helping it transition from a small start-up to a successful research and development organization.
Education and Expertise
Elizabeth Evans holds a Doctor of Philosophy (PhD) in Pathology from the University of Rochester School of Medicine and Dentistry, where she studied from 1999 to 2001. She also earned a Master of Science (MS) in Microbiology and Immunology from the same institution, completing her studies from 1996 to 1999. Earlier, she obtained a Bachelor of Science (BS) in Biology and Anthropology from the State University of New York at Stony Brook, where she studied from 1989 to 1992.
Background
Before her current roles at Vaccinex, Elizabeth Evans served as Vice President of Discovery Research. She has also worked as a research scientist at the University of Rochester. Her academic background in biology, anthropology, microbiology, immunology, and pathology has provided her with a strong foundation for her work in the biotechnology sector.
Clinical Trials and Research Contributions
Elizabeth Evans has been actively involved in supporting clinical trials focused on immuno-oncology and neurodegenerative diseases, including Huntington's Disease and Alzheimer's Disease. She has played a key role in the clinical development of human therapeutic monoclonal antibodies at Vaccinex, contributing to advancements in treatment options for these conditions.